Dennis Yamashita - Oct 18, 2024 Form 4 Insider Report for Kintara Therapeutics, Inc. (KTRA)

Role
Chief Scientific Officer
Signature
/s/ Dan Dearborn as Power of Attorney for Dennis Yamashita
Stock symbol
KTRA
Transactions as of
Oct 18, 2024
Transactions value $
$0
Form type
4
Date filed
10/22/2024, 09:12 PM

Derivative Securities (e.g., puts, calls, warrants, options, convertible securities)

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Underlying Class Amount Exercise Price Ownership Footnotes
transaction KTRA Options (Right to Buy) Award $0 +197K $0.00 197K Oct 18, 2024 Common Stock 197K $3.69 Direct F1, F2
* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id Content
F1 Securities issued upon closing of the transactions contemplated by the Agreement and Plan of Merger, dated as of April 2, 2024 (the "Merger Agreement"), among the Issuer (fka "Kintara Therapeutics, Inc."), Kayak Mergeco, Inc., a Delaware corporation and wholly owned subsidiary of Issuer ("Merger Sub"), and TuHURA Biosciences, Inc., a Delaware corporation ("Private TuHURA"). Under the terms of the Merger Agreement, on October 18, 2024, Merger Sub merged with and into Private TuHURA (the "Merger") with Private TuHURA surviving the Merger as a wholly owned subsidiary of the Issuer. Upon the closing of the Merger, securities of Private TuHURA were converted into the right to receive securities of the Issuer as set forth in the Merger Agreement. The Issuer subsequently changed its name to "TuHURA Biosciences, Inc."
F2 One-third of the stock options become exercisable on the first, second, and third anniversary of January 19, 2024.